Xenios Pediatrics - Innovations for Pediatric Care

Because kids will be kids

Heilbronn, (PresseBox) - After founding Xenios AG earlier this year, Novalung GmbH and Medos Medizintechnik AG have now jointly started the Xenios Pediatrics business unit.

Xenios Pediatrics combines the leading extracorporeal systems from Medos and Novalung and thus creates a unique ECMO offering for pediatric intensive care. Neonates, babies and children with severe pulmonary or cardiac failure can be treated using extracorporeal membrane oxygenation (ECMO). With the help of this extracorporeal organ replacement procedure sufficient oxygenation can be maintained for days or weeks.

Based on years of experience in the field, Novalung and Medos have recognized the need for advanced extracorporeal therapy systems in pediatric and neonatal care. The next step is the decision to develop new system solutions together with the established pediatric ECMO centers.

Xenios Pediatrics focusses exclusively on the pediatric and neonatal field and offers a unique portfolio of products for patient-specific solutions for the entire spectrum of extracorporeal cardiopulmonary support. Xenios Pediatrics will continue to pursue a close working relationship with doctors and nurses to launch an innovation initiative for pediatric ECMO.

Website Promotion

Xenios AG

About Xenios Xenios is dedicated to translating medical need into pioneering therapies and devices together with caregivers and patients. The holding represents a fast paced, sustainable group of companies with a robust technology base and an ambitious product pipeline. Xenios strives to be the technology and market leader in extracorporeal therapies. The core technology platforms are artificial lungs, blood pumps, vascular access devices, temperature control, and biocompatible surfaces. The Xenios brands, Novalung, Medos and Xenios Pediatrics, provide extracorporeal therapy systems that respond to the medical need in pulmonary and cardiac failure. Xenios AG was founded in 2013 by Novalung GmbH and Medos AG.

Press releases you might also be interested in

Weitere Informationen zum Thema "Medizintechnik":

„AppliedAI“-Initiative will KI in Deutschland voranbringen

Je­des Jahr ein deut­sches Start-up aus dem Um­feld der Künst­li­chen In­tel­li­genz (KI) in die in­ter­na­tio­na­len Top-100-Lis­ten brin­gen – so lau­tet ei­nes der Zie­le, das sich die In­i­tia­ti­ve „Ap­p­lie­dAI“ auf die Fah­ne ge­schrie­ben hat. Un­ter der Äg­i­de der Baye­ri­schen Staats­re­gie­rung und mit Un­ter­stüt­zung der Tech­ni­schen Uni­ver­si­tät Mün­chen ko­ope­rie­ren 26 For­schung­s­ein­rich­tun­gen und Kon­zer­ne.


Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.